Cargando…
Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT
BACKGROUND: Diagnostic guidelines for isolated cardiac sarcoidosis (iCS) were first proposed in 2016, but there are few reports on the imaging and prognosis of iCS. This study aimed to evaluate the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984349/ https://www.ncbi.nlm.nih.gov/pubmed/35804283 http://dx.doi.org/10.1007/s12350-022-03034-0 |
_version_ | 1784900727785652224 |
---|---|
author | Okada, Tomohisa Kawaguchi, Naoto Miyagawa, Masao Matsuoka, Marika Tashiro, Rami Tanabe, Yuki Kido, Tomoyuki Miyoshi, Toru Higashi, Haruhiko Inoue, Takeshi Okayama, Hideki Yamaguchi, Osamu Kido, Teruhito |
author_facet | Okada, Tomohisa Kawaguchi, Naoto Miyagawa, Masao Matsuoka, Marika Tashiro, Rami Tanabe, Yuki Kido, Tomoyuki Miyoshi, Toru Higashi, Haruhiko Inoue, Takeshi Okayama, Hideki Yamaguchi, Osamu Kido, Teruhito |
author_sort | Okada, Tomohisa |
collection | PubMed |
description | BACKGROUND: Diagnostic guidelines for isolated cardiac sarcoidosis (iCS) were first proposed in 2016, but there are few reports on the imaging and prognosis of iCS. This study aimed to evaluate the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in predicting iCS prognosis. METHODS AND RESULTS: We retrospectively reviewed the clinical and imaging data of 306 consecutive patients with suspected CS who underwent FDG PET/CT with a dedicated preparation protocol and included 82 patients (55 with systemic sarcoidosis including cardiac involvement [sCS], 27 with iCS) in the study. We compared the FDG PET/CT findings between the two groups. We examined the relationship between the CS type and the rate of adverse cardiac events. The iCS group had a significantly lower target-to-background ratio than the sCS group (P = 0.0010). The event-free survival rate was significantly lower in the iCS group than the sCS group (log-rank test, P < 0.0001). iCS was identified as an independent prognostic factor for adverse events (hazard ratio 3.82, P = 0.0059). CONCLUSION: iCS was an independent prognostic factor for adverse cardiac events in patients with CS. The clinical diagnosis of iCS based on FDG PET/CT and new guidelines may be important. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-022-03034-0. |
format | Online Article Text |
id | pubmed-9984349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-99843492023-03-05 Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT Okada, Tomohisa Kawaguchi, Naoto Miyagawa, Masao Matsuoka, Marika Tashiro, Rami Tanabe, Yuki Kido, Tomoyuki Miyoshi, Toru Higashi, Haruhiko Inoue, Takeshi Okayama, Hideki Yamaguchi, Osamu Kido, Teruhito J Nucl Cardiol Original Article BACKGROUND: Diagnostic guidelines for isolated cardiac sarcoidosis (iCS) were first proposed in 2016, but there are few reports on the imaging and prognosis of iCS. This study aimed to evaluate the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in predicting iCS prognosis. METHODS AND RESULTS: We retrospectively reviewed the clinical and imaging data of 306 consecutive patients with suspected CS who underwent FDG PET/CT with a dedicated preparation protocol and included 82 patients (55 with systemic sarcoidosis including cardiac involvement [sCS], 27 with iCS) in the study. We compared the FDG PET/CT findings between the two groups. We examined the relationship between the CS type and the rate of adverse cardiac events. The iCS group had a significantly lower target-to-background ratio than the sCS group (P = 0.0010). The event-free survival rate was significantly lower in the iCS group than the sCS group (log-rank test, P < 0.0001). iCS was identified as an independent prognostic factor for adverse events (hazard ratio 3.82, P = 0.0059). CONCLUSION: iCS was an independent prognostic factor for adverse cardiac events in patients with CS. The clinical diagnosis of iCS based on FDG PET/CT and new guidelines may be important. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-022-03034-0. Springer International Publishing 2022-07-08 2023 /pmc/articles/PMC9984349/ /pubmed/35804283 http://dx.doi.org/10.1007/s12350-022-03034-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Okada, Tomohisa Kawaguchi, Naoto Miyagawa, Masao Matsuoka, Marika Tashiro, Rami Tanabe, Yuki Kido, Tomoyuki Miyoshi, Toru Higashi, Haruhiko Inoue, Takeshi Okayama, Hideki Yamaguchi, Osamu Kido, Teruhito Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title | Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title_full | Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title_fullStr | Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title_full_unstemmed | Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title_short | Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT |
title_sort | clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated fdg pet/ct |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984349/ https://www.ncbi.nlm.nih.gov/pubmed/35804283 http://dx.doi.org/10.1007/s12350-022-03034-0 |
work_keys_str_mv | AT okadatomohisa clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT kawaguchinaoto clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT miyagawamasao clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT matsuokamarika clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT tashirorami clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT tanabeyuki clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT kidotomoyuki clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT miyoshitoru clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT higashiharuhiko clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT inouetakeshi clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT okayamahideki clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT yamaguchiosamu clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct AT kidoteruhito clinicalfeaturesandprognosisofisolatedcardiacsarcoidosisdiagnosedusingnewguidelineswithdedicatedfdgpetct |